115066-14-3
115066-14-3 結(jié)構(gòu)式
基本信息
6-CYANO-7-NITROQUINOXALINE-2,3-DIONE 2NA
6-CYANO-7-NITROQUINOXALINE-2,3-DIONE DISODIUM
6-CYANO-7-NITROQUINOXALINE-2,3-DIONE DISODIUM SALT
CNQX
CNQX 2NA
CNQX DISODIUM
CNQX DISODIUM SALT
FG-9065
CNQX DISODIUM KAINATE/AMPA RECEPTOR
CNQX (FG-9065) (6-CYANO-7-NITROQUINO
6-CYANO-7-NITROQUINOXALINE-2,3 (1H,4H)-DIONE
6-Cyano-7-nitroquinoxaline-2,3-dione, FG-9065
2,3-Dioxo-7-nitroquinoxaline-6-carbonitrile
6-Nitro-7-cyanoquinoxaline-2,3-dione
CNOX
1,2,3,4-Tetrahydro-7-nitro-2,3-dioxo-6-quinoxalinecarbonitrile
7-Nitro-2,3-dihydroxyquinoxaline-6-carbonitrile
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表
IC50: 0.3 μM (AMPA) and 1.5 μM (kainate receptor)
CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices.
CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.
CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices.
CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.
| Animal Model: | Male Wistar rats weighing 180-200 g |
| Dosage: | 0.75, 1.5, and 3 mg/kg |
| Administration: | IP; 20 min before testing |
| Result: | Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |